2,044
Participants
Start Date
September 30, 2021
Primary Completion Date
January 18, 2022
Study Completion Date
September 9, 2022
aQIV
Participants receive a 0.5-mL intramuscular dose of aQIV on Day 1
Comparator QIV
Participants receive a 0.5-mL intramuscular dose of Comparator QIV on Day 1
84011 Meridian Clinical Research, Endwell
84008 United Medical Associates, Binghamton
84001 Meridian Clinical Research, Savannah
84010 Headlands Research Orlando, Orlando
84005 JEM Research Institute, Atlantis
84013 Coastal Clinical Research, Inc., Mobile
84003 Meridian Clinical Research, Sioux City
84006 Alliance for Multispecialty Research, Kansas City
84004 Meridian Clinical Research, Omaha
84009 Meridian Clinical Research, Lincoln
84002 Meridian Clinical Research, Norfolk
84007 Alliance for Multispecialty Research, Tempe
23302 Vee Family Doctors Centre, Paide
23301 Innomedica OÜ - Outpatient, Tallinn
23303 Al Mare Perearstikeskus OÜ, Tallinn
23304 Merelahe Family Doctors Centre, Tallinn
23306 Center for Clinical and Basic Research, Tallinn
23305 Clinical Research Center - Vaccine Trials, Tartu
27602 Klinische Forschung Berlin, Berlin
27603 Emovis GmbH, Berlin
27608 Klinische Forschung Dresden GmbH, Dresden
27609 IKF Pneumologie GmbH & Co. KG, Frankfurt
27611 Siteworks GmbH, Fulda
27601 Klinische Forschung Hamburg GmbH, Hamburg
27605 Clinical Research Hamburg GmbH, Hamburg
27604 Klinische Forschung Hannover-Mitte GmbH, Hanover
27607 Siteworks GmbH, Hanover
27606 SIBAmed GmbH & Co KG, Leipzig
27610 Studienzentrum Leitz Triderm, Stuttgart
Seqirus
INDUSTRY